ILEX Oncology (ILXO) Reports Q3 2004 Results; Clofarabine FDA Panel Hearing Set For December
10/19/2005 5:11:52 PM
ILEX(TM) Oncology Inc. (Nasdaq:ILXO) today reported that global net sales of CAMPATH(R)/MABCAMPATH(R) (alemtuzumab) recorded by Schering AG, Germany (NYSE:SHR) (FSE:SCH) and its U.S. affiliate Berlex Laboratories Inc. totaled $18.2 million during the third quarter of 2004. That compares to sales of $16.1 million for the same quarter a year ago, a 13% increase. For the first nine months of 2004, global net sales of CAMPATH totaled $56.5 million, up 6% from $53.3 million in the first nine months of 2003.
comments powered by